Ex-InterMune Inc. (ITMN:US) Controller Bruce Tomlinson was sued by the U.S. Securities and Exchange Commission for allegedly disclosing tips in 2010 about the drug Esbriet to a former business associate.
Tomlinson, who was vice president of finance and InterMune’s principal accounting officer, tipped Michael Sarkesian, a Swiss businessman, about nonpublic information on the progress of a European Union regulatory committee’s review of InterMune’s application to market Esbriet in Europe, the SEC said in a complaint filed today in federal court in San Francisco. Esbriet is used to treat a fatal lung disease.
Sarkesian contacted Quorne Ltd., a British Virgin Islands-based broker whose only shareholder is a Cyprus trust maintained for the benefit of Sarkesian’s wife, to buy InterMune call options that resulted in a profit of $616,000, the SEC said.
The value of the options soared in December 2010 on news that the EU committee had approved the application.
The commission is seeking a court order permanently blocking Tomlinson from violating securities laws or acting as an officer or director of a publicly traded company and unspecific civil penalties. Sarkesian wasn’t sued in the case.
Colleen Mahoney, an attorney for Tomlinson, didn’t immediately return an e-mail seeking comment on the complaint.
The case is SEC v. Tomlinson, 13-02549, U.S. District Court (San Francisco).
To contact the reporter on this story: Karen Gullo in San Francisco at firstname.lastname@example.org
To contact the editor responsible for this story: Michael Hytha at email@example.com